Keep the medicine name beside the product name
FDA has approved products containing semaglutide (Ozempic, Wegovy). Tirzepatide also has approved products, named Mounjaro and Zepbound. Each product’s label sets out its own approved uses.
The group name GLP-1 refers to drugs that copy a hormone which affects hunger and blood sugar.
Compounding means preparing a drug to order. A licensed pharmacist or doctor, or registered facility, can do that work.
Neither tirzepatide nor semaglutide injection had a national shortage listing on September 26, 2026. A shop running out locally does not create that FDA listing.
Ask why a compounded version is being proposed
Federal law bars pharmacies from routinely making copies, or making them in large amounts, when the medicine is already available. A changed version may be treated differently if the prescriber decides the change makes an important medical difference for the named patient. A lower price does not meet that test.
Consider the dye-allergy example FDA gives: a person needs a medicine but is allergic to its dye. Making it without the dye may meet that need. Ask your prescriber to explain the proposed change and the important medical difference for you. This example is not permission to copy any medicine.
Does adding a vitamin automatically make a different medicine?Reveal the distinction
Adding a vitamin to semaglutide does not automatically avoid the federal copy rule, FDA explained in April 2026. The prescriber must write down what changed for the named patient and why that change makes an important medical difference for them.
Studies are testing the peptide retatrutide for weight care. In its September 2026 record, FDA says federal law bars using it in compounding. Evidence has not led the agency to find that it works safely for any condition.
A useful next question
How do I compare the full cost?